China bars GSK from national drug bulk-buy programme over drug irregularities
CHINA has blocked British drugmaker GSK from participating in its national drug procurement programme from Oct 31, 2022 to Apr 29, 2024, state television CCTV reported on Monday (Oct 31).
CCTV said authorities had decided to do so after a batch of dutasteride soft capsules supplied by GSK failed a recent quality check by the National Medical Products Administration.
GSK did not immediately respond to a request for comment.
Beijing runs a national scheme where global pharmaceutical companies and Chinese generic drugmakers vie to sell their products in bulk at public hospitals. REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices
Dying salmon trouble Norway’s vast fish-farm industry
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too
Billionaire Geiger is said to near US$7 billion L’Occitane buyout